Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study

Y. Imai, T. Chou, K. Tobinai, R. Tanosaki, Y. Morishima, M. Ogura, C. Shimazaki, M. Taniwaki, A. Hiraoka, M. Tanimoto, T. Koike, K. Kogawa, H. Hirai, T. Yoshida, K. Tamura, K. Kishi, T. Hotta

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The purging efficacy of positive selection of autologous CD34+ PBSC with a clinical scale method of magnetic-activated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34+ cells post-selection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34+ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19+ cell and CD20+ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34+ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 × 109/1 neutrophils of 10 days (range 8-13) and 20 × 109/1 platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.

Original languageEnglish
Pages (from-to)479-487
Number of pages9
JournalBone Marrow Transplantation
Volume35
Issue number5
DOIs
Publication statusPublished - Mar 1 2005

Keywords

  • Autologous PBSCT
  • CD34 selection
  • High-dose chemotherapy
  • Magnetic-activated cell sorting system
  • Non-Hodgkin's lymphoma
  • Phase II study

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Isolation and transplantation of highly purified autologous peripheral CD34<sup>+</sup> progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study'. Together they form a unique fingerprint.

  • Cite this

    Imai, Y., Chou, T., Tobinai, K., Tanosaki, R., Morishima, Y., Ogura, M., Shimazaki, C., Taniwaki, M., Hiraoka, A., Tanimoto, M., Koike, T., Kogawa, K., Hirai, H., Yoshida, T., Tamura, K., Kishi, K., & Hotta, T. (2005). Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): Results of Japanese phase II study. Bone Marrow Transplantation, 35(5), 479-487. https://doi.org/10.1038/sj.bmt.1704819